Milestone Pharmaceuticals Dividend

Dividend criteria checks 0/6

Milestone Pharmaceuticals hat in der Vergangenheit keine Dividende gezahlt.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	2.3%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-US$1.00
Dividend yield forecast in 3Y	n/a

Recent dividend updates

No updates

Recent updates

We Think Milestone Pharmaceuticals (NASDAQ:MIST) Can Afford To Drive Business Growth

Jun 24

We're Hopeful That Milestone Pharmaceuticals (NASDAQ:MIST) Will Use Its Cash Wisely

Feb 25

We're Interested To See How Milestone Pharmaceuticals (NASDAQ:MIST) Uses Its Cash Hoard To Grow

Aug 25

Companies Like Milestone Pharmaceuticals (NASDAQ:MIST) Are In A Position To Invest In Growth

Apr 02

What You Need To Know About Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Investor Composition

Jan 15

First patient enrolled in Milestone Pharmaceuticals' late-stage study of etripamil in PSVT

Nov 18

Milestone Pharmaceuticals EPS beats by $0.09

Nov 13

Stability and Growth of Payments

Fetching dividends data

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von MIST in der Vergangenheit stabil geblieben ist.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von MIST gestiegen sind.

Dividend Yield vs Market

Milestone Pharmaceuticals Dividend Yield vs Market

How does MIST dividend yield compare to the market?
Segment	Dividend Yield
Company (MIST)	n/a
Market Bottom 25% (US)	1.5%
Market Top 25% (US)	4.7%
Industry Average (Pharmaceuticals)	2.3%
Analyst forecast in 3 Years (MIST)	n/a

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von MIST im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von MIST im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Earnings Payout to Shareholders

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von MIST, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Cash Payout to Shareholders

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da MIST keine Ausschüttungen gemeldet hat.

Discover strong dividend paying companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Milestone Pharmaceuticals Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

Price target increased by 21% to US$13.00

Milestone Pharmaceuticals Inc. Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia

Milestone Pharmaceuticals Inc., Annual General Meeting, Jun 13, 2024

Full year 2023 earnings: EPS misses analyst expectations

New major risk - Revenue and earnings growth

No longer forecast to breakeven

New minor risk - Shareholder dilution

Milestone Pharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of $29.966667 million.

Milestone Pharmaceuticals Inc. Announces Plan to Resubmit NDA for Etripamil for the Treatment of Psvt

Price target decreased by 21% to US$10.75

Forecast to breakeven in 2026

Milestone Pharmaceuticals Receives Refusal to File Letter from U.S. FDA for New Drug Application for Etripamil in the Treatment of PSVT

Price target increased by 13% to US$16.00

Alta Advisers Sends a Letter to Milestone Pharmaceuticals

Insufficient new directors

New minor risk - Market cap size

Milestone Pharmaceuticals Inc. Announces Submission of New Drug Application to the U.S. FDA for Etripamil

Is Milestone Pharmaceuticals (NASDAQ:MIST) A Risky Investment?

New minor risk - Profitability

Price target increased by 12% to US$16.75

New minor risk - Share price stability

Milestone Pharmaceuticals Inc. Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in the Lancet

Price target decreased by 9.0% to US$14.20

Chief Commercial Officer recently bought US$94k worth of stock

We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate

Milestone Pharmaceuticals Inc. Announces the Retirement of Francis Plat as Chief Scientific Officer, Effective December 31, 2022

Milestone Pharmaceuticals Inc. Announces New Data from Phase 3 RAPID Trial of Etripamil Nasal Spray in Patients with PSVT During Late-Breaking Session at the AHA Scientific Sessions 2022

Independent Non-Executive Director recently bought US$80k worth of stock

Milestone Pharmaceuticals Announces Positive Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with Paroxysmal Supraventricular Tachycardia

Price target increased to US$15.40

We're Keeping An Eye On Milestone Pharmaceuticals' (NASDAQ:MIST) Cash Burn Rate

We Think Milestone Pharmaceuticals (NASDAQ:MIST) Can Afford To Drive Business Growth

Milestone Pharmaceuticals Announces Presentation of Data from Phase 3 Node-302 Study of Etripamil for the Treatment of Psvt

Milestone Pharmaceuticals Inc., Annual General Meeting, Jun 23, 2022

We're Hopeful That Milestone Pharmaceuticals (NASDAQ:MIST) Will Use Its Cash Wisely

Milestone Pharmaceuticals Appoints David Bharucha as Chief Medical Officer

We're Interested To See How Milestone Pharmaceuticals (NASDAQ:MIST) Uses Its Cash Hoard To Grow

Consensus revenue estimates increase to US$15.0m

Milestone Pharmaceuticals Announces Late-Breaker Oral Presentation of NODE-301 Data at ACC.21

Companies Like Milestone Pharmaceuticals (NASDAQ:MIST) Are In A Position To Invest In Growth

New 90-day low: US$6.52

New 90-day high: US$7.67

What You Need To Know About Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) Investor Composition

Milestone Pharmaceuticals Inc. Announces First Patient Enrolled in RAPID, a Pivotal Phase 3 Study of Etripamil in PSVT

First patient enrolled in Milestone Pharmaceuticals' late-stage study of etripamil in PSVT

Milestone Pharmaceuticals Inc. Announces Board Changes

Milestone Pharmaceuticals EPS beats by $0.09

New 90-day low: US$6.00

Milestone Pharmaceuticals Inc. Appoints Lisa Giles and Robert Wills to Board of Directors, Effective October 1, 2020

Milestone Pharmaceuticals Inc. announced that it has received $24.933448 million in funding from RTW Investments, LP

Milestone Pharmaceuticals Inc. announced that it expects to receive $24.933448 million in funding from RTW Investments, LP

New 90-day high - US$8.91

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies